Nothing Special   »   [go: up one dir, main page]

B Goulet et al., 2013 - Google Patents

At the “junction” of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression

B Goulet et al., 2013

View PDF
Document ID
1918466759299009720
Author
B Goulet B
Kothary R
J Parks R
Publication year
Publication venue
Current molecular medicine

External Links

Snippet

Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Similar Documents

Publication Publication Date Title
B Goulet et al. At the “junction” of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression
Cartoni et al. The mammalian-specific protein Armcx1 regulates mitochondrial transport during axon regeneration
Krus et al. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy
Scekic‐Zahirovic et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss
Ackermann et al. Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality
Zaltieri et al. α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons
d'Ydewalle et al. Spinal muscular atrophy therapeutics: where do we stand?
Gagnon et al. Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts
Xi et al. Impaired dopaminergic neuron development and locomotor function in zebrafish with loss of pink1 function
Le et al. Temporal requirement for high SMN expression in SMA mice
Boido et al. Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy
Gorbatyuk et al. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme
Feng et al. Aberrant splicing in neurological diseases
Tuxworth et al. Attenuating the DNA damage response to double-strand breaks restores function in models of CNS neurodegeneration
Liu et al. The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy
Sato-Yamada et al. A SARM1-mitochondrial feedback loop drives neuropathogenesis in a Charcot-Marie-Tooth disease type 2A rat model
Zhou et al. Elevated levels of miR-144-3p induce cholinergic degeneration by impairing the maturation of NGF in Alzheimer’s disease
Kharouf et al. The hyperpolarization‐activated cyclic nucleotide‐gated 4 channel as a potential anti‐seizure drug target
McCormack et al. Survival motor neuron deficiency slows myoblast fusion through reduced myomaker and myomixer expression
Stavrou et al. CMT1A current gene therapy approaches and promising biomarkers
Zheng et al. NMDA-induced neuronal survival is mediated through nuclear factor IA in mice
EP3027753B1 (en) Neurocalcin delta inhibitors and therapeutic and non-therapeutic uses thereof
Rashid et al. Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches
Yun et al. Targeting upregulated RNA binding protein RCAN1. 1: a promising strategy for neuroprotection in acute ischemic stroke
WO2018205927A1 (en) Use of potassium ion channel inhibitor for treatment of depression and pharmaceutical composition